Молекулярно-генетические маркеры в  прогнозировании и лечении рака простаты

  • И. Е. Седаков Республиканский онкологический центр им. проф. Г. В. Бондаря
  • Н. Г. Семикоз ГОО ВПО «Донецкий национальный медицинский университет имени М. Горького»
  • А. В. Мотрий Республиканский онкологический центр им. проф. Г. В. Бондаря
  • А. А. Анищенко ГОО ВПО «Донецкий национальный медицинский университет имени М. Горького»
  • О. Н. Маслова Республиканский онкологический центр им. проф. Г. В. Бондаря
  • А. В. Башеев Республиканский онкологический центр им. проф. Г. В. Бондаря
  • М. О. Мотрий Республиканский онкологический центр им. проф. Г. В. Бондаря
  • О. В. Колычева ГОО ВПО «Донецкий национальный медицинский университет имени М. Горького»

Аннотация

Рак предстательной железы (РПЖ) является наиболее распространенным раком у мужчин и ведущей причиной смерти от злокачественных опухолей. Раннее обнаружение РПЖ в значительной степени определяется широко используемым анализом крови на простатический специфический антиген (ПСА), а для окончательного диагноза проводится биопсия. Рак простаты протекает бессимптомно на ранней стадии заболевания, имеет различные клинико-патологические особенности и особенности прогрессирования и характеризуется большой подгруппой вялотекущего типа рака. Следовательно, очень важно разработать индивидуальный подход для раннего выявления, стратификации заболевания и прогнозирования ответа на лечение. Был достигнут значительный прогресс в открытии биомаркеров рака простаты, в основном благодаря достижениям в области геномных технологий и опухолевой ткани. Развитие этих анализов открыло новые возможности для улучшения диагностики рака простаты, прогноза и решений о лечении. Открывая захватывающие возможности, эти разработки также создают уникальные проблемы с точки зрения выбора и включения этих анализов терапию пациентов с раком простаты.пациентов с раком простаты.

Литература

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590.
2. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262.
3. Larrañaga N., Galceran J., Ardanaz E., Franch P., Navarro C., Sánchez M.J., Pastor-Barriuso R., Martos C., Rodríguez L., Vilardell L., et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: Impact on mortality. Ann. Oncol. 2010;21:iii83–iii89. doi: 10.1093/annonc/mdq087
4. Hugosson J., Carlsson S., Aus G., Bergdahl S., Khatami A., Lodding P., Pihl C.G., Stranne J., Holmberg E., Lilja H. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–732. doi: 10.1016/S1470-2045(10)70146-7.
5. Graif T., Loeb S., Roehl K.A., Gashti S.N., Griffin C., Yu X., Catalona W.J. Under Diagnosis and Over Diagnosis of Prostate Cancer. J. Urol. 2007;178:88–92. doi: 10.1016/j.juro.2007.03.017.
6. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., et al. Screening and prostate-cancer mortality in a randomized european study. N. Engl. J. Med. 2009;360:1320–1328. doi: 10.1056/NEJMoa0810084.
7. Loeb S., Catalona W.J. The Prostate Health Index: A new test for the detection of prostate cancer. Ther. Adv. Urol. 2014;6:74–77. doi: 10.1177/1756287213513488
8. Boegemann M., Stephan C., Cammann H., Vincendeau S., Houlgatte A., Jung K., Blanchet J.S., Semjonow A. The percentage of prostate-specific antigen (PSA) isoform [−2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men. BJU Int. 2016;117:72–79. doi: 10.1111/bju.13139.
9. De La Calle C., Patil D., Wei J.T., Scherr D.S., Sokoll L., Chan D.W., Siddiqui J., Mosquera J.M., Rubin M.A., Sanda M.G. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy Naïve men. J. Urol. 2015;194:65–72. doi: 10.1016/j.juro.2015.01.091.
10. Carroll P.R., Parsons J.K., Andriole G., Bahnson R.R., Castle E.P., Catalona W.J., Dahl D.M., Davis J.W., Epstein J.I., Etzioni R.B., et al. Prostate Cancer Early Detection, Version 2.2016: Featured Updates to the NCCN Guidelines. J. Natl. Compr. Cancer Netw. 2016;14:509–519. doi: 10.6004/jnccn.2016.0060.
11. Lin D., McGee S., Rieger-Christ K. et al. PI-06 Late-Breaking Abstract: The 4KscoreTM test as a predictor of high-grade prostate cancer on biopsy. J Urol 2014;191(4):e224.
12. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra224. doi: 10.1126/scitranslmed.3007094
13. Ellis W.J., Pfitzenmaier J., Colli J., Arfman E., Lange P.H., Vessella R.L. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology. 2003;61:277–281. doi: 10.1016/S0090-4295(02)02291-4.
14. Morgan T.M., Lange P.H., Vessella R.L. Detection and characterization of circulating and disseminated prostate cancer cells. Front. Biosci. 2007;12:3000–3009. doi: 10.2741/2290.
15. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W., Pienta K.J., Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008;14:6302–6309. doi: 10.1158/1078-0432.CCR-08-0872.
16. Punnoose E.A., Ferraldeschi R., Szafer-Glusman E., Tucker E.K., Mohan S., Flohr P., Riisnaes R., Miranda S., Figueiredo I., Rodrigues D.N., et al. Pten loss in circulating tumour cells correlates with pten loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br. J. Cancer. 2015;113:1225–1233. doi: 10.1038/bjc.2015.332.
17. Krebs M.G., Metcalf R.L., Carter L., Brady G., Blackhall F.H., Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. 2014;11:129–144. doi: 10.1038/nrclinonc.2013.253.
18. Lohr J.G., Adalsteinsson V.A., Cibulskis K., Choudhury A.D., Rosenberg M., Cruz-Gordillo P., Francis J.M., Zhang C.Z., Shalek A.K., Satija R., et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 2014;32:479–484. doi: 10.1038/nbt.2892.
19. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., Chen Y., Mohammad T.A., Fedor H.L., Lotan T.L., et al. Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014;371:1028–1038. doi: 10.1056/NEJMoa1315815.
20. Thalgott M., Rack B., Maurer T., Souvatzoglou M., Eiber M., Kress V., Heck M.M., Andergassen U., Nawroth R., Gschwend J.E., et al. Detection of circulating tumor cells in different stages of prostate cancer. J. Cancer Res. Clin. Oncol. 2013;139:755–763. doi: 10.1007/s00432-013-1377-5.
21. Xu B, Niu X, Zhang X, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011;350:207-13.
22. Marks L.S., Fradet Y., Lim Deras I., Blase A., Mathis J., Aubin S.M.J., Cancio A.T., Desaulniers M., Ellis W.J., Rittenhouse H., et al. PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. Urology. 2007;69:532–535. doi: 10.1016/j.urology.2006.12.014.
23. Gittelman M.C., Hertzman B., Bailen J., Williams T., Koziol I., Henderson R.J., Efros M., Bidair M., Ward J.F. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study. J. Urol. 2013;190:64–69. doi: 10.1016/j.juro.2013.02.018.
24. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., Masse B., Piche L., Chypre C. Upm3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311–315. doi: 10.1016/j.urology.2004.03.052.
25. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., Kiemeney L.A., Witjes J.A., Schalken J.A. Dd3(pca3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003;44:8–15. doi: 10.1016/S0302-2838(03)00201-X.
26. Nakanishi H., Groskopf J., Fritsche H.A., Bhadkamkar V., Blase A., Kumar S.V., Davis J.W., Troncoso P., Rittenhouse H., Babaian R.J. Pca3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J. Urol. 2008;179:1804–1809. doi: 10.1016/j.juro.2008.01.013.
27. van Gils M.P., Cornel E.B., Hessels D., Peelen W.P., Witjes J.A., Mulders P.F., Rittenhouse H.G., Schalken J.A. Molecular pca3 diagnostics on prostatic fluid. Prostate. 2007;67:881–887. doi: 10.1002/pros.20564.
28. Whitman E.J., Groskopf J., Ali A., Chen Y., Blase A., Furusato B., Petrovics G., Ibrahim M., Elsamanoudi S., Cullen J., et al. Pca3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 2008;180:1975–1978. doi: 10.1016/j.juro.2008.07.060.
29. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., Brentano S., Mathis J., Pham J., Meyer T., et al. Aptima pca3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006;52:1089–1095. doi: 10.1373/clinchem.2005.063289.
30. Leyten G.H., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., et al. Prospective multicentre evaluation of pca3 and tmprss2-erg gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2014;65:534–542. doi: 10.1016/j.eururo.2012.11.014
31. Filella X., Foj L., Milà M. et al. PCA3 in the detection and management of early prostate cancer. Tumour Biol 2013;34(3):1337–47
32. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. // Science. 2005. Vol. 310. P. 644–648
33. Rice K.R., Chen Y., Ali A., Whitman E.J., Blase A., Ibrahim M., Elsamanoudi S., Brassell S., Furusato B., Stingle N., et al. Evaluation of the ets-related gene mrna in urine for the detection of prostate cancer. Clin. Cancer Res. 2010;16:1572–1576. doi: 10.1158/1078-0432.CCR-09-2191.
34. Rice K.R., Chen Y., Ali A., Whitman E.J., Blase A., Ibrahim M., Elsamanoudi S., Brassell S., Furusato B., Stingle N., et al. Evaluation of the ets-related gene mrna in urine for the detection of prostate cancer. Clin. Cancer Res. 2010;16:1572–1576. doi: 10.1158/1078-0432.CCR-09-2191.
35. Leyten G.H., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., et al. Prospective multicentre evaluation of pca3 and tmprss2-erg gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 2014;65:534–542. doi: 10.1016/j.eururo.2012.11.014.
36. Sanguedolce F., Cormio A., Brunelli M., D’Amuri A., Carrieri G., Bufo P., Cormio L. Urine tmprss2: Erg fusion transcript as a biomarker for prostate cancer: Literature review. Clin. Genitour. Cancer. 2016;14:117–121. doi: 10.1016/j.clgc.2015.12.001.
37. Yang Z., Yu L., Wang Z. Pca3 and tmprss2-erg gene fusions as diagnostic biomarkers for prostate cancer. Chin. J. Cancer Res. 2016;28:65–71.
38. Salami S.S., Schmidt F., Laxman B., Regan M.M., Rickman D.S., Scherr D., Bueti G., Siddiqui J., Tomlins S.A., Wei J.T., et al. Combining urinary detection of tmprss2:Erg and pca3 with serum psa to predict diagnosis of prostate cancer. Urol. Oncol. 2013;31:566–571. doi: 10.1016/j.urolonc.2011.04.001.
39. Tomlins S.A., Aubin S.M., Siddiqui J., Lonigro R.J., Sefton-Miller L., Miick S., Williamsen S., Hodge P., Meinke J., Blase A., et al. Urine tmprss2:Erg fusion transcript stratifies prostate cancer risk in men with elevated serum psa. Sci. Transl. Med. 2011;3:94ra72. doi: 10.1126/scitranslmed.3001970.
40. Demichelis F., Fall K., Perner S., Andren O., Schmidt F., Setlur S.R., Hoshida Y., Mosquera J.M., Pawitan Y., Lee C., et al. Tmprss2:Erg gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599. doi: 10.1038/sj.onc.1210237.
41. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., Feng Z., Parnes H.L., Coltman C.A., Jr. Assessing prostate cancer risk: Results from the prostate cancer prevention trial. J. Natl. Cancer Inst. 2006;98:529–534. doi: 10.1093/jnci/djj131.
42. Sanda M.G., Feng Z., Howard D.H., Tomlins S.A., Sokoll L.J., Chan D.W., Regan M.M., Groskopf J., Chipman J., Patil D.H., et al. Association between combined tmprss2:Erg and pca3 rna urinary testing and detection of aggressive prostate cancer. JAMA Oncol. 2017;3:1085–1093. doi: 10.1001/jamaoncol.2017.0177.
43. Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., et al. Urine tmprss2:Erg plus pca3 for individualized prostate cancer risk assessment. Eur. Urol. 2016;70:45–53. doi: 10.1016/j.eururo.2015.04.039.
44. McLeod D.G., Petrovics G. Re: Association between combined tmprss2:Erg and pca3 rna urinary testing and detection of aggressive prostate cancer. Eur. Urol. 2018;73:301–302. doi: 10.1016/j.eururo.2017.09.035.
45. Bryant R.J., Pawlowski T., Catto J.W. et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106(4):768–74.
46. . Mhawech-Fauceglia P., Zhang S., Terracciano L. et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50(4):472–83
47. Gu Z., Thomas G., Yamashiro J. et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19(10):1288–96.
48. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, . Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888–93.
49. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, . Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33–9.
50. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928–34.
51. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, . Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010;105:462–7.
52. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS. Cancer and the heat shock response. Eur J Cancer 1994;30A:1884–91.
53. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, . Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005;27:263–72.
54. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, . Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS 2008;116:888–95.
55. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005;280:33097–100.
56. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, . Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 2010;176:393–401.
57. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366–81.
58. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, . Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733–7.
59. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010;2:17–33.
60. Serpa Neto A, Tobias-Machado M, Wroclawski ML, Affonso Fonseca FL, Teixeira GK, Dal Moro Amarante R, . HER-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J Urol Epub 2010 Jul 19.
61. Shipitsin M., Small C., Choudhury S., Giladi E., Friedlander S., Nardone J., Hussain S., Hurley A.D., Ernst C., Huang Y.E., et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer. 2014;111:1201–1212. doi: 10.1038/bjc.2014.396.
62. Blume-Jensen P., Berman D.M., Rimm D.L., Shipitsin M., Putzi M., Nifong T.P., Small C., Choudhury S., Capela T., Coupal L., et al. Biology of Human Tumors Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin. Cancer Res. 2015;21:2591–2600. doi: 10.1158/1078-0432.CCR-14-2603.
63. Cuzick J., Swanson G.P., Fisher G., Brothman A.R., Berney D.M., Reid J.E., Mesher D., Speights V.O., Stankiewicz E., Foster C.S., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 2011;12:245–255. doi: 10.1016/S1470-2045(10)70295-3.
64. Cuzick J., Berney D.M., Fisher G., Mesher D., Møller H., Reid J.E., Perry M., Park J., Younus A., Gutin A., et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer. 2012;106:1095–1099. doi: 10.1038/bjc.2012.39.
65. Eggener S.E., Rumble R.B., Armstrong A.J., Morgan T.M., Crispino T., Cornford P., van der Kwast T., Grignon D.J., Rai A.J., Agarwal N., et al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J. Clin. Oncol. 2020;13:1474–1494. doi: 10.1200/JCO.19.02768.
66. Cuzick J., Swanson G.P., Fisher G., Brothman A.R., Berney D.M., Reid J.E., Mesher D., Speights V.O., Stankiewicz E., Foster C.S., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol. 2011;12:245–255. doi: 10.1016/S1470-2045(10)70295-3.
67. Cooperberg M.R., Simko J.P., Cowan J.E., Reid J.E., Djalilvand A., Bhatnagar S., Gutin A., Lanchbury J.S., Swanson G.P., Stone S., et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 2013;31:1428–1434. doi: 10.1200/JCO.2012.46.4396.
68. Freedland S.J., Gerber L., Reid J., Welbourn W., Tikishvili E., Park J., Younus A., Gutin A., Sangale Z., Lanchbury J.S., et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2013;86:848–853. doi: 10.1016/j.ijrobp.2013.04.043.
69. Advice N. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression. BJU Int. 2018;122:173–180. doi: 10.1111/bju.14452.
70. López I.H., Parada D., Gallardo P., Gascón M., Besora A., Peña K., Riu F., Arquez Pianetta M., Abuchaibe O., Torres Royò L., et al. Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. Reports Pract. Oncol. Radiother. 2017;22:251–257. doi: 10.1016/j.rpor.2017.02.003.
71. Van Den Eeden S.K., Lu R., Zhang N., Quesenberry C.P., Jr., Shan J., Han J.S., Tsiatis A.C., Leimpeter A.D., Lawrence H.J., Febbo P.G., et al. A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur. Urol. 2018;73:129–138. doi: 10.1016/j.eururo.2017.09.013.
72. Cullen J., Rosner I.L., Brand T.C., Zhang N., Tsiatis A.C., Moncur J., Ali A., Chen Y., Knezevic D., Maddala T., et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur. Urol. 2015;68:123–131. doi: 10.1016/j.eururo.2014.11.030.
73. Karnes R.J., Bergstralh E.J., Davicioni E., Ghadessi M., Buerki C., Mitra A.P., Crisan A., Erho N., Vergara I.A., Lam L.L., et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J. Urol. 2013;190:2047–2053. doi: 10.1016/j.juro.2013.06.017.
74. Den R.B., Yousefi K., Trabulsi E.J., Abdollah F., Choeurng V., Feng F.Y., Dicker A.P., Lallas C.D., Gomella L.G., Davicioni E., et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J. Clin. Oncol. 2015;33:944–951. doi: 10.1200/JCO.2014.59.0026.
75. Erho N., Crisan A., Vergara I.A., Mitra A.P., Ghadessi M., Buerki C., Bergstralh E.J., Kollmeyer T., Fink S., Haddad Z., et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8:e66855. doi: 10.1371/journal.pone.0066855.
76. Klein E.A., Haddad Z., Yousefi K., Lam L.L., Wang Q., Choeurng V., Palmer-Aronsten B., Buerki C., Davicioni E., Li J., et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology. 2016;90:148–152. doi: 10.1016/j.urology.2016.01.012.
77. Gore J.L., du Plessis M., Santiago-Jiménez M., Yousefi K., Thompson D.J.S., Karsh L., Lane B.R., Franks M., Chen D.Y.T., Bandyk M., et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. 2017;123:2850–2859. doi: 10.1002/cncr.30665.
78. Marascio J., Spratt D.E., Zhang J., Trabulsi E.J., Le T., Sedzorme W.S., Beeler W.H., Davicioni E., Dabbas B., Lin D.W., et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2019 doi: 10.1038/s41391-019-0185-7.
79. . Ross A.E., Feng F.Y., Ghadessi M. et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014;17(1)64–9.
80. Den R.B., Feng F.Y., Showalter T.N. et al. Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. Int J Radiat Oncol Elsevier 2014;89(5):1038–46.
81. Den R.B., Feng F.Y., Showalter T.N. et al. Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. Int J Radiat Oncol Elsevier 2014;89(5):1038–46.
Опубликована
2020-12-03
Как цитировать
СЕДАКОВ, И. Е. et al. Молекулярно-генетические маркеры в  прогнозировании и лечении рака простаты. Новообразование, [S.l.], v. 12, n. 4, p. 158-167, дек. 2020. ISSN 2521-117X. Доступно на: <http://donetsk-onco.com/neoplasm/index.php/Neoplasm/article/view/349>. Дата доступа: 16 апр. 2021 doi: https://doi.org/10.26435/neoplasm.v12i4.349.
Раздел
Оригинальные статьи

Наиболее читаемые статьи этого автора (авторов)

Особенность: этот модуль требует, что бы был включен хотя бы один модуль статистики/отчетов. Если ваши модули статистики возвращают больше одной метрики, то пожалуйста также выберите главную метрику на странице настроек сайта администратором и/или на страницах настройки управляющего журналом.